CureVac NV Ordinary Shares
CVAC: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$9.34 | Gqrhk | Ntsxgvqf |
CureVac Progresses mRNA Candidates, Reports Positive Phase 1 Oncology Results; $15.40 FVE
CureVac is focused on expanding its mRNA pipeline candidates, and preliminary data from its phase 1 study of oncology candidate CV8102 demonstrates a positive safety profile and promising results showing CV8102’s ability to mobilize the immune system against tumors. Five out of 30 patients experienced a partial response to CV8102, and responses appeared durable for up to one year from the start of treatment. We assign CV8102 a 10% probability of approval in our base case; if approved, we forecast it could reach the market as early as 2025.